FHIR IG analytics| Package | hl7.fhir.uv.ebm |
| Resource Type | Citation |
| Id | Citation-179630.json |
| FHIR Version | R6 |
No resources found
No resources found
Note: links and images are rebased to the (stated) source
Generated Narrative: Citation 179630
version: 19; Last updated: 2025-10-13 12:34:35+0000
Profile: JournalArticleCitation
ArtifactPublicationStatus: Active
identifier: FEvIR Object Identifier/179630, https://pubmed.ncbi.nlm.nih.gov/26092557, Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.15.30
version: 1.0.0-ballot3
title: 26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.
status: Active
date: 2026-02-10 14:00:26+0000
author: Computable Publishing®: MEDLINE-to-FEvIR Converter:
publisher: HL7 International / Clinical Decision Support
contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss
description:
This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.
| Code | Value[x] |
| Citation Classification Type: fevir-platform-use (FEvIR Platform Use) | Medline Base |
jurisdiction: World
copyright:
https://creativecommons.org/licenses/by-nc-sa/4.0/
approvalDate: 2016-04-14
lastReviewDate: 2024-02-10
classification
type: Citation Source
classifier: MEDLINE
classification
type: MEDLINE Citation Owner
classifier: National Library of Medicine, Index Section
currentState: Medline Citation Status of Medline, PubMed PublicationStatus of ppublish
statusDate
activity: PubMed Pubstatus of Received
period: ?? --> 2015-02-20
statusDate
activity: PubMed Pubstatus of Revised
period: ?? --> 2015-05-08
statusDate
activity: PubMed Pubstatus of Accepted
period: ?? --> 2015-05-11
statusDate
activity: PubMed Pubstatus of Entrez
period: ?? --> 2015-06-21 06:00:00+0000
statusDate
activity: PubMed Pubstatus of Pubmed
period: ?? --> 2015-06-21 06:00:00+0000
statusDate
activity: PubMed Pubstatus of Medline
period: ?? --> 2016-04-15 06:00:00+0000
citedArtifact
identifier:
https://pubmed.ncbi.nlm.nih.gov/26092557,https://doi.org/10.1016/j.urolonc.2015.05.012, pii/S1078-1439(15)00235-5Titles
Type Text Primary title Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.
Abstracts
Type Text Copyright Primary human use BACKGROUND AND OBJECTIVE: Sequential tissue biopsies taken during clinical trials of novel systemic anticancer therapies for advanced prostate cancer (PCa) may aid pharmacodynamic evaluation and biomarker discovery. We conducted a single institution phase-II open-labeled randomized study to assess the safety, tolerability, and early efficacy of docetaxel chemotherapy plus androgen deprivation therapy (ADT) vs. ADT alone for patients with advanced non-castration-resistant PCa with sequential prostatic biopsies. PATIENTS AND METHODS: We randomized 30 patients with newly diagnosed high-grade locally advanced or metastatic (cT3-4/N0-1/M0-1) PCa to receive ADT with (n = 15) or without (n = 15) docetaxel. Transrectal ultrasound-guided prostatic biopsies were taken at randomization and ~22 weeks after treatment initiation. Primary end point: biochemical response rate. Secondary end points: time to progression and tumor profiling. RESULTS: Both treatments appear to be well tolerated, and there was no difference in mean nadir prostate-specific antigen and time to prostate-specific antigen relapse between treatment arms (P>0.05). No adverse effects of pre- and post-treatment prostatic biopsies were observed. The study was neither designed nor sufficiently powered to demonstrate statistically significant differences in oncological outcomes or safety profiles between the 2 treatment arms. CONCLUSIONS: Despite the lack of statistical power, our study suggests that docetaxel and ADT in combination may be well tolerated with apparently similar short-term efficacy compared with ADT alone for high-grade locally advanced or metastatic non-castration-resistant PCa, Sequential prostatic biopsies may provide tissue for tumor profiling to yield mechanistic or prognostic insights relating to novel systemic anticancer therapies.
Copyright © 2015 Elsevier Inc. All rights reserved.
publicationForm
publishedIn
type: Periodical
identifier: Electronic ISSN Type/1873-2496, ISOAbbreviation/Urol Oncol, ISSN Linking/1078-1439, Medline Title Abbreviation/Urol Oncol, NLM Unique ID/9805460
title: Urologic oncology
publisherLocation: United States
citedMedium: Internet
volume: 33
issue: 8
articleDate: 2015-08
pageString: 337.e1-6
publicationForm
citedMedium: Internet without issue
articleDate: 2015-06-16
webLocation
classifier: Abstract
webLocation
classifier: DOI Based
classification
type: Publishing Model
classifier: Print Electronic
classification
type: Keyword
artifactAssessment: Keywords provided by NOTNLM
classification
type: Chemical
classifier: Androgen Antagonists, Taxoids, Docetaxel
classification
type: MeSH heading
artifactAssessment: ArtifactAssessment: artifact[x] = this resource
classification
type: Publication type
classifier: Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
classification
type: Knowledge Artifact Type
classifier: Journal Article
artifactAssessment: Classifier added by Computable Publishing LLC
classification
type: Citation subset
classifier: IM
contributorship
complete: true
entry
contributor: Rajan P
forenameInitials: P
affiliation: Institute of Cancer Sciences, University of Glasgow, UK. Electronic address: p.rajan@beatson.gla.ac.uk.
entry
contributor: Frew JA
forenameInitials: JA
affiliation: Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK.
entry
contributor: Wilson JM
forenameInitials: JM
affiliation: Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK.
entry
contributor: Azzabi AS
forenameInitials: AS
affiliation: Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK.
entry
contributor: McMenemin RM
forenameInitials: RM
affiliation: Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK.
entry
contributor: Stockley J
forenameInitials: J
affiliation: Institute of Cancer Sciences, University of Glasgow, UK.
entry
contributor: Soomro NA
forenameInitials: NA
affiliation: Newcastle Urology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK.
entry
contributor: Durkan G
forenameInitials: G
affiliation: Newcastle Urology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK.
entry
contributor: Pedley ID
forenameInitials: ID
affiliation: Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK.
entry
contributor: Leung HY
forenameInitials: HY
affiliation: Institute of Cancer Sciences, University of Glasgow, UK; Cancer Research UK Beatson Institute, Bearsden, UK. Electronic address: h.leung@beatson.gla.ac.uk.
Generated Narrative: ArtifactAssessment #keywords0
content
classifier: Androgen deprivation therapy
content
classifier: Docetaxel
content
classifier: Prostate cancer
content
classifier: Prostatic biopsy
Generated Narrative: Practitioner #contributor0
name: Prabhakar Rajan
Generated Narrative: Practitioner #contributor1
name: John A Frew
Generated Narrative: Practitioner #contributor2
name: James M Wilson
Generated Narrative: Practitioner #contributor3
name: Ashraf S T Azzabi
Generated Narrative: Practitioner #contributor4
name: Rhona M McMenemin
Generated Narrative: Practitioner #contributor5
name: Jacqueline Stockley
Generated Narrative: Practitioner #contributor6
name: Naeem A Soomro
Generated Narrative: Practitioner #contributor7
name: Garrett Durkan
Generated Narrative: Practitioner #contributor8
name: Ian D Pedley
Generated Narrative: Practitioner #contributor9
name: Hing Y Leung
Generated Narrative: ArtifactAssessment #meshHeading0
content
type: components (if present) include qualifier codings
classifier: Aged
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Androgen Antagonists
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: administration & dosage
Components
Type Classifier is Major topic No component
type: qualifier
classifier: therapeutic use
Components
Type Classifier is Major topic Yes content
type: components (if present) include qualifier codings
classifier: Biopsy
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Docetaxel
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Feasibility Studies
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Humans
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Male
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Middle Aged
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Prostatic Neoplasms
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: drug therapy
Components
Type Classifier is Major topic Yes component
type: qualifier
classifier: surgery
Components
Type Classifier is Major topic Yes content
type: components (if present) include qualifier codings
classifier: Taxoids
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: administration & dosage
Components
Type Classifier is Major topic No component
type: qualifier
classifier: therapeutic use
Components
Type Classifier is Major topic Yes
{
"resourceType": "Citation",
"id": "179630",
"meta": {
"versionId": "19",
"lastUpdated": "2025-10-13T12:34:35.118Z",
"profile": [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
"text": {
"status": "extensions",
"div": "<!-- snip (see above) -->"
},
"contained": [
{
"resourceType": "ArtifactAssessment",
"id": "keywords0",
"artifactReference": {
"reference": "#",
"type": "Citation"
},
"content": [
{
"classifier": [
{
"text": "Androgen deprivation therapy"
}
]
},
{
"classifier": [
{
"text": "Docetaxel"
}
]
},
{
"classifier": [
{
"text": "Prostate cancer"
}
]
},
{
"classifier": [
{
"text": "Prostatic biopsy"
}
]
}
]
},
{
"resourceType": "Practitioner",
"id": "contributor0",
"name": [
{
"family": "Rajan",
"given": [
"Prabhakar"
]
}
]
},
{
"resourceType": "Practitioner",
"id": "contributor1",
"name": [
{
"family": "Frew",
"given": [
"John A"
]
}
]
},
{
"resourceType": "Practitioner",
"id": "contributor2",
"name": [
{
"family": "Wilson",
"given": [
"James M"
]
}
]
},
{
"resourceType": "Practitioner",
"id": "contributor3",
"name": [
{
"family": "Azzabi",
"given": [
"Ashraf S T"
]
}
]
},
{
"resourceType": "Practitioner",
"id": "contributor4",
"name": [
{
"family": "McMenemin",
"given": [
"Rhona M"
]
}
]
},
{
"resourceType": "Practitioner",
"id": "contributor5",
"name": [
{
"family": "Stockley",
"given": [
"Jacqueline"
]
}
]
},
{
"resourceType": "Practitioner",
"id": "contributor6",
"name": [
{
"family": "Soomro",
"given": [
"Naeem A"
]
}
]
},
{
"resourceType": "Practitioner",
"id": "contributor7",
"name": [
{
"family": "Durkan",
"given": [
"Garrett"
]
}
]
},
{
"resourceType": "Practitioner",
"id": "contributor8",
"name": [
{
"family": "Pedley",
"given": [
"Ian D"
]
}
]
},
{
"resourceType": "Practitioner",
"id": "contributor9",
"name": [
{
"family": "Leung",
"given": [
"Hing Y"
]
}
]
},
{
"resourceType": "ArtifactAssessment",
"id": "meshHeading0",
"artifactReference": {
"reference": "#",
"type": "Citation"
},
"content": [
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D000368",
"display": "Aged",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D000726",
"display": "Androgen Antagonists",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
},
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "Q000008",
"display": "administration & dosage"
}
]
}
],
"component": [
{
"type": {
"text": "is Major topic"
},
"classifier": [
{
"coding": [
{
"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code": "C49487",
"display": "No"
}
]
}
]
}
]
},
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "Q000627",
"display": "therapeutic use"
}
]
}
],
"component": [
{
"type": {
"text": "is Major topic"
},
"classifier": [
{
"coding": [
{
"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code": "C49488",
"display": "Yes"
}
]
}
]
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D001706",
"display": "Biopsy",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D000077143",
"display": "Docetaxel",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D005240",
"display": "Feasibility Studies",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D006801",
"display": "Humans",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D008297",
"display": "Male",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D008875",
"display": "Middle Aged",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D011471",
"display": "Prostatic Neoplasms",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
},
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "Q000188",
"display": "drug therapy"
}
]
}
],
"component": [
{
"type": {
"text": "is Major topic"
},
"classifier": [
{
"coding": [
{
"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code": "C49488",
"display": "Yes"
}
]
}
]
}
]
},
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "Q000601",
"display": "surgery"
}
]
}
],
"component": [
{
"type": {
"text": "is Major topic"
},
"classifier": [
{
"coding": [
{
"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code": "C49488",
"display": "Yes"
}
]
}
]
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D043823",
"display": "Taxoids",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
},
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "Q000008",
"display": "administration & dosage"
}
]
}
],
"component": [
{
"type": {
"text": "is Major topic"
},
"classifier": [
{
"coding": [
{
"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code": "C49487",
"display": "No"
}
]
}
]
}
]
},
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "Q000627",
"display": "therapeutic use"
}
]
}
],
"component": [
{
"type": {
"text": "is Major topic"
},
"classifier": [
{
"coding": [
{
"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code": "C49488",
"display": "Yes"
}
]
}
]
}
]
}
]
}
]
}
],
"extension": [
{
"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status",
"valueCodeableConcept": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type",
"code": "active",
"display": "Active"
}
]
}
}
],
"url": "https://fevir.net/resources/Citation/179630",
"identifier": [
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/v2-0203",
"code": "ACSN",
"display": "Accession ID"
}
],
"text": "FEvIR Object Identifier"
},
"system": "https://fevir.net/FOI",
"value": "179630",
"assigner": {
"display": "Computable Publishing LLC"
}
},
{
"system": "https://pubmed.ncbi.nlm.nih.gov",
"value": "26092557"
},
{
"system": "urn:ietf:rfc:3986",
"value": "urn:oid:2.16.840.1.113883.4.642.40.44.15.30"
}
],
"version": "1.0.0-ballot3",
"title": "26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.",
"status": "active",
"date": "2026-02-10T14:00:26+00:00",
"author": [
{
"name": "Computable Publishing®: MEDLINE-to-FEvIR Converter"
}
],
"publisher": "HL7 International / Clinical Decision Support",
"contact": [
{
"name": "HL7 International / Clinical Decision Support",
"telecom": [
{
"system": "url",
"value": "http://www.hl7.org/Special/committees/dss"
}
]
}
],
"description": "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"useContext": [
{
"code": {
"system": "http://terminology.hl7.org/CodeSystem/citation-classification-type",
"code": "fevir-platform-use",
"display": "FEvIR Platform Use"
},
"valueCodeableConcept": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/citation-artifact-classifier",
"code": "medline-base",
"display": "Medline Base",
"userSelected": false
}
]
}
}
],
"jurisdiction": [
{
"coding": [
{
"system": "http://unstats.un.org/unsd/methods/m49/m49.htm",
"code": "001",
"display": "World"
}
]
}
],
"copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/",
"approvalDate": "2016-04-14",
"lastReviewDate": "2024-02-10",
"classification": [
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/citation-classification-type",
"code": "citation-source",
"display": "Citation Source"
}
]
},
"classifier": [
{
"text": "MEDLINE"
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/citation-classification-type",
"code": "medline-owner",
"display": "MEDLINE Citation Owner"
}
]
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value",
"code": "NLM",
"display": "National Library of Medicine, Index Section",
"userSelected": false
}
]
}
]
}
],
"currentState": [
{
"coding": [
{
"system": "http://hl7.org/fhir/citation-status-type",
"code": "medline-medline",
"display": "Medline Citation Status of Medline"
}
]
},
{
"coding": [
{
"system": "http://hl7.org/fhir/citation-status-type",
"code": "pubmed-publication-status-ppublish",
"display": "PubMed PublicationStatus of ppublish"
}
]
}
],
"statusDate": [
{
"activity": {
"coding": [
{
"system": "http://hl7.org/fhir/citation-status-type",
"code": "pubmed-pubstatus-received",
"display": "PubMed Pubstatus of Received"
}
]
},
"period": {
"end": "2015-02-20"
}
},
{
"activity": {
"coding": [
{
"system": "http://hl7.org/fhir/citation-status-type",
"code": "pubmed-pubstatus-revised",
"display": "PubMed Pubstatus of Revised"
}
]
},
"period": {
"end": "2015-05-08"
}
},
{
"activity": {
"coding": [
{
"system": "http://hl7.org/fhir/citation-status-type",
"code": "pubmed-pubstatus-accepted",
"display": "PubMed Pubstatus of Accepted"
}
]
},
"period": {
"end": "2015-05-11"
}
},
{
"activity": {
"coding": [
{
"system": "http://hl7.org/fhir/citation-status-type",
"code": "pubmed-pubstatus-entrez",
"display": "PubMed Pubstatus of Entrez"
}
]
},
"period": {
"end": "2015-06-21T06:00:00.000Z"
}
},
{
"activity": {
"coding": [
{
"system": "http://hl7.org/fhir/citation-status-type",
"code": "pubmed-pubstatus-pubmed",
"display": "PubMed Pubstatus of Pubmed"
}
]
},
"period": {
"end": "2015-06-21T06:00:00.000Z"
}
},
{
"activity": {
"coding": [
{
"system": "http://hl7.org/fhir/citation-status-type",
"code": "pubmed-pubstatus-medline",
"display": "PubMed Pubstatus of Medline"
}
]
},
"period": {
"end": "2016-04-15T06:00:00.000Z"
}
}
],
"citedArtifact": {
"identifier": [
{
"system": "https://pubmed.ncbi.nlm.nih.gov",
"value": "26092557"
},
{
"system": "https://doi.org",
"value": "10.1016/j.urolonc.2015.05.012"
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/v2-0203",
"code": "ACSN",
"display": "Accession ID"
}
],
"text": "pii"
},
"value": "S1078-1439(15)00235-5"
}
],
"title": [
{
"type": [
{
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/title-type",
"code": "primary",
"display": "Primary title"
}
]
}
],
"text": "Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer."
}
],
"abstract": [
{
"type": [
{
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-abstract-type",
"code": "primary-human-use",
"display": "Primary human use"
}
]
}
],
"text": "**BACKGROUND AND OBJECTIVE:** Sequential tissue biopsies taken during clinical trials of novel systemic anticancer therapies for advanced prostate cancer (PCa) may aid pharmacodynamic evaluation and biomarker discovery. We conducted a single institution phase-II open-labeled randomized study to assess the safety, tolerability, and early efficacy of docetaxel chemotherapy plus androgen deprivation therapy (ADT) vs. ADT alone for patients with advanced non-castration-resistant PCa with sequential prostatic biopsies.\n**PATIENTS AND METHODS:** We randomized 30 patients with newly diagnosed high-grade locally advanced or metastatic (cT3-4/N0-1/M0-1) PCa to receive ADT with (n = 15) or without (n = 15) docetaxel. Transrectal ultrasound-guided prostatic biopsies were taken at randomization and ~22 weeks after treatment initiation. Primary end point: biochemical response rate. Secondary end points: time to progression and tumor profiling.\n**RESULTS:** Both treatments appear to be well tolerated, and there was no difference in mean nadir prostate-specific antigen and time to prostate-specific antigen relapse between treatment arms (P>0.05). No adverse effects of pre- and post-treatment prostatic biopsies were observed. The study was neither designed nor sufficiently powered to demonstrate statistically significant differences in oncological outcomes or safety profiles between the 2 treatment arms.\n**CONCLUSIONS:** Despite the lack of statistical power, our study suggests that docetaxel and ADT in combination may be well tolerated with apparently similar short-term efficacy compared with ADT alone for high-grade locally advanced or metastatic non-castration-resistant PCa, Sequential prostatic biopsies may provide tissue for tumor profiling to yield mechanistic or prognostic insights relating to novel systemic anticancer therapies.",
"copyright": "Copyright © 2015 Elsevier Inc. All rights reserved."
}
],
"publicationForm": [
{
"publishedIn": {
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/published-in-type",
"code": "D020492",
"display": "Periodical"
}
]
},
"identifier": [
{
"type": {
"coding": [
{
"system": "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#issn",
"code": "Electronic",
"display": "Electronic"
}
],
"text": "Electronic ISSN Type"
},
"system": "https://portal.issn.org",
"value": "1873-2496"
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/v2-0203",
"code": "XX",
"display": "Organization identifier"
}
],
"text": "ISOAbbreviation"
},
"system": "https://www.issn.org/services/online-services/access-to-the-ltwa/",
"value": "Urol Oncol"
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/v2-0203",
"code": "XX",
"display": "Organization identifier"
}
],
"text": "ISSN Linking"
},
"system": "https://www.issn.org/understanding-the-issn/assignment-rules/the-issn-l-for-publications-on-multiple-media/",
"value": "1078-1439"
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/v2-0203",
"code": "XX",
"display": "Organization identifier"
}
],
"text": "Medline Title Abbreviation"
},
"system": "https://www.nlm.nih.gov/tsd/cataloging/contructitleabbre.html",
"value": "Urol Oncol"
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/v2-0203",
"code": "XX",
"display": "Organization identifier"
}
],
"text": "NLM Unique ID"
},
"system": "https://locatorplus.gov/cgi-bin/Pwebrecon.cgi?DB=local",
"value": "9805460"
}
],
"title": "Urologic oncology",
"publisherLocation": "United States"
},
"citedMedium": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-medium",
"code": "internet",
"display": "Internet"
}
]
},
"volume": "33",
"issue": "8",
"articleDate": "2015-08",
"pageString": "337.e1-6"
},
{
"citedMedium": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-medium",
"code": "internet-without-issue",
"display": "Internet without issue"
}
]
},
"articleDate": "2015-06-16"
}
],
"webLocation": [
{
"classifier": [
{
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/artifact-url-classifier",
"code": "abstract",
"display": "Abstract"
}
]
}
],
"url": "https://pubmed.ncbi.nlm.nih.gov/26092557/"
},
{
"classifier": [
{
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/artifact-url-classifier",
"code": "doi-based",
"display": "DOI Based"
}
]
}
],
"url": "https://doi.org/10.1016/j.urolonc.2015.05.012"
}
],
"classification": [
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "publishing-model",
"display": "Publishing Model",
"userSelected": false
}
]
},
"classifier": [
{
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/citation-artifact-classifier",
"code": "Print-Electronic",
"display": "Print Electronic",
"userSelected": false
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "keyword",
"display": "Keyword",
"userSelected": false
}
]
},
"artifactAssessment": [
{
"reference": "#keywords0",
"type": "ArtifactAssessment",
"display": "Keywords provided by NOTNLM"
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "chemical",
"display": "Chemical",
"userSelected": false
}
]
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D000726",
"display": "Androgen Antagonists",
"userSelected": false
}
]
},
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D043823",
"display": "Taxoids",
"userSelected": false
}
]
},
{
"coding": [
{
"system": "https://www.cas.org/support/documentation/chemical-substances",
"code": "15H5577CQD",
"userSelected": false
},
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D000077143",
"display": "Docetaxel",
"userSelected": false
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
]
},
"artifactAssessment": [
{
"reference": "#meshHeading0",
"type": "ArtifactAssessment"
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "publication-type",
"display": "Publication type"
}
]
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D017427",
"display": "Clinical Trial, Phase II",
"userSelected": false
}
]
},
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D016428",
"display": "Journal Article",
"userSelected": false
}
]
},
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D016449",
"display": "Randomized Controlled Trial",
"userSelected": false
}
]
},
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D013485",
"display": "Research Support, Non-U.S. Gov't",
"userSelected": false
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "knowledge-artifact-type",
"display": "Knowledge Artifact Type",
"userSelected": false
}
]
},
"classifier": [
{
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/citation-artifact-classifier",
"code": "D016428",
"display": "Journal Article",
"userSelected": false
}
]
}
],
"artifactAssessment": [
{
"display": "Classifier added by Computable Publishing LLC"
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "citation-subset",
"display": "Citation subset",
"userSelected": false
}
]
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset",
"code": "IM",
"display": "IM",
"userSelected": false
}
]
}
]
}
],
"contributorship": {
"complete": true,
"entry": [
{
"contributor": {
"reference": "#contributor0",
"type": "Practitioner",
"display": "Rajan P"
},
"forenameInitials": "P",
"affiliation": [
{
"display": "Institute of Cancer Sciences, University of Glasgow, UK. Electronic address: p.rajan@beatson.gla.ac.uk."
}
]
},
{
"contributor": {
"reference": "#contributor1",
"type": "Practitioner",
"display": "Frew JA"
},
"forenameInitials": "JA",
"affiliation": [
{
"display": "Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK."
}
]
},
{
"contributor": {
"reference": "#contributor2",
"type": "Practitioner",
"display": "Wilson JM"
},
"forenameInitials": "JM",
"affiliation": [
{
"display": "Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK."
}
]
},
{
"contributor": {
"reference": "#contributor3",
"type": "Practitioner",
"display": "Azzabi AS"
},
"forenameInitials": "AS",
"affiliation": [
{
"display": "Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK."
}
]
},
{
"contributor": {
"reference": "#contributor4",
"type": "Practitioner",
"display": "McMenemin RM"
},
"forenameInitials": "RM",
"affiliation": [
{
"display": "Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK."
}
]
},
{
"contributor": {
"reference": "#contributor5",
"type": "Practitioner",
"display": "Stockley J"
},
"forenameInitials": "J",
"affiliation": [
{
"display": "Institute of Cancer Sciences, University of Glasgow, UK."
}
]
},
{
"contributor": {
"reference": "#contributor6",
"type": "Practitioner",
"display": "Soomro NA"
},
"forenameInitials": "NA",
"affiliation": [
{
"display": "Newcastle Urology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK."
}
]
},
{
"contributor": {
"reference": "#contributor7",
"type": "Practitioner",
"display": "Durkan G"
},
"forenameInitials": "G",
"affiliation": [
{
"display": "Newcastle Urology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK."
}
]
},
{
"contributor": {
"reference": "#contributor8",
"type": "Practitioner",
"display": "Pedley ID"
},
"forenameInitials": "ID",
"affiliation": [
{
"display": "Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK."
}
]
},
{
"contributor": {
"reference": "#contributor9",
"type": "Practitioner",
"display": "Leung HY"
},
"forenameInitials": "HY",
"affiliation": [
{
"display": "Institute of Cancer Sciences, University of Glasgow, UK; Cancer Research UK Beatson Institute, Bearsden, UK. Electronic address: h.leung@beatson.gla.ac.uk."
}
]
}
]
}
}
}